Business Description
Aptose Biosciences Inc
NAICS : 325412
SIC : 3741
Compare
Compare
Traded in other countries / regions
APS.CanadaLTIA.Germany0UI8.UKAPTO.USA IPO Date
1992-07-30Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 204.68 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 7.3 | |||||
| 3-Year EPS without NRI Growth Rate | 6.8 | |||||
| 3-Year FCF Growth Rate | 12.9 | |||||
| 3-Year Book Growth Rate | 27.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.64 | |||||
| 9-Day RSI | 64.72 | |||||
| 14-Day RSI | 58.07 | |||||
| 6-1 Month Momentum % | 6.74 | |||||
| 12-1 Month Momentum % | -48.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.53 | |||||
| Quick Ratio | 5.53 | |||||
| Cash Ratio | 5.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -34.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -85.28 | |||||
| ROA % | -75.28 | |||||
| ROIC % | -5018.21 | |||||
| ROC (Joel Greenblatt) % | -8040.22 | |||||
| ROCE % | -85.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.29 | |||||
| Price-to-Tangible-Book | 1.29 | |||||
| EV-to-EBIT | -0.24 | |||||
| EV-to-Forward-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.25 | |||||
| EV-to-Forward-EBITDA | -0.11 | |||||
| EV-to-FCF | -0.35 | |||||
| Price-to-Net-Current-Asset-Value | 1.29 | |||||
| Price-to-Net-Cash | 1.34 | |||||
| Earnings Yield (Greenblatt) % | -416.67 |
How Aptose Biosciences Inc (APTO) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APTO
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.61 | ||
| Beta | 1.67 | ||
| Volatility % | 78.98 | ||
| 14-Day RSI | 58.07 | ||
| 14-Day ATR ($) | 0.047241 | ||
| 20-Day SMA ($) | 0.574998 | ||
| 12-1 Month Momentum % | -48.4 | ||
| 52-Week Range ($) | 0.4255 - 1.55 | ||
| Shares Outstanding (Mil) | 92.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aptose Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aptose Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aptose Biosciences Inc Frequently Asked Questions
What is Aptose Biosciences Inc(APTO)'s stock price today?
The current price of APTO is $0.64. The 52 week high of APTO is $1.55 and 52 week low is $0.43.
When is next earnings date of Aptose Biosciences Inc(APTO)?
The next earnings date of Aptose Biosciences Inc(APTO) is 2023-05-09 Est..
Does Aptose Biosciences Inc(APTO) pay dividends? If so, how much?
Aptose Biosciences Inc(APTO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
